Abstract 2620
Background
Absenteeism and presenteeism (A/P) are scales related to health problems and professional activity in patients and in healthy individuals. For cancer patients in the age of maximum labor productivity (18 to 65 years old), A/P are possibly affected by quality of care, type of cancer, and selection of treatments. The objectives of this study were to clarify via questionnaire the association between quality-of-life (QOL) and A/P, as well as the changes of A/P during clinical course in cancer patients.
Methods
A/P were measured using the validated Japanese version of the World Health Organization Health and Work Performance Questionnaire (WHO-HPQ). QOL was measured using the 5-level EQ-5D version via a portable device with the Apple ResearchKit app.
Results
We received 3983 survey results (healthy individuals, 297; cancer patients, 3686). Presenteeism was clearly different between cancer patients and healthy individuals (absolute/relative presenteeism: 59.3/0.93 and 65.8/1.01, respectively). Examination of the relationship between QOL and A/P using Spearman’s rank correlation coefficient analysis indicated that QOL is significantly correlated with relative presenteeism (r = 0.40, P < 0.001). The labor performance of pancreatic carcinoma patients was low (absolute/relative absenteeism: 68.7/0.29, absolute/relative presenteeism: 43.8/0.68). The A/P in patients with receiving chemotherapy were not maintained compared to in patients receiving surgical treatment (absolute/relative absenteeism: 39/8/0.16 vs. 17.8/0.02, p = 0.04, absolute/relative presenteeism: 55.5/0.83 vs. 62.8/0.95, p < 0.001, respectively).
Conclusions
WHO-HPQ can be used to measure the labor performance in cancer patients. Moreover, A/P was strongly affected by type of cancers and selection of treatments.
Clinical trial identification
Editorial acknowledgement
The research was supported by Project Mirai Cancer Research Grants and Health Labour Sciences Research Grant.
Legal entity responsible for the study
Shunsuke Kondo.
Funding
Project Mirai Cancer Research Grants and Health Labour Sciences Research Grant.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract